Summary
We analysed the status of the p53 gene and protein in eight newly established acute myeloid leukaemia (AML) cell lines representing blast cells of either de novo leukaemia patients in first remission or patients with relapsed and chemotherapy-resistant disease causing their death. There were no mutations in the p53 gene in any of the cell lines as analysed by single-strand conformation polymorphism of amplified exons 5–8. However, the p53 protein was clearly and consistently expressed in all of these cell lines, as shown by immunohistochemistry, Western blotting and flow cytometry. The consistently expressed p53 protein was located in both the nucleus and the cytoplasm of all the cell lines and, as shown by flow cytometry, it was mostly in a conformation typical of the mutated protein. These AML cell lines offer a tool for studying the production and function of the p53 protein and its possible role in cell cycle regulation and chemoresistance as well as in the regulation of apoptosis in AML.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bargonetti, J., Friedman, P. N., Kern, S. E., Vogelstein, B. & Prives, C. (1991). Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65: 1083–1091.
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, O. A. G., Gralnick, H. D. & Sultan, C. (1976). Proposals for the classification of acute leukemias. Br J Haematol 33: 451–458.
Bi, S., Lanza, F. & Goldman, J. M. (1994). The involvement of tumor suppressor p53 in normal and chronic myelogenous leukemia hemopoiesis. Cancer Res 54: 582–586.
Castren, K., Vähäkangas, K., Heikkinen, E. & Ranki, A. (1998). Absence of p53 mutations in benign and premalignant male genital lesions with overexpressed p53 protein. Int J Cancer 77: 674–678.
Chowdary, D. R., Dermody, J. J., Jha, K. K. & Ozer, H. L. (1994). Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol 14: 1997–2003.
Chresta, C. M., Masters, J. R. W. & Hickman, J. A. (1996). Hypersensitivity of human testicular tumors to etoposide induced apoptosis is associated with functional p53 and a high bax:bcl-2 ratio. Cancer Res 56: 1834–1841.
Dive, C. (1997). Avoidance of apoptosis as a mechanism of drug resistance. J Intern Med 242: (suppl. 740) 139–145.
Döhner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., Volkmann, M., Galle, P. R., Postka, A., Hunstein, W. & Lichter, P. (1995). p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85: 1580–1589.
Elonen, E., for the Finnish Leukemia Group (1993). Intensive chemotherapy of adult acute myelogenous leukemia: a randomized trial between 4 and 8 cycles. Blood 82: 328a
Fenaux, P., Preudhomme, C., Quiquandron, I., Jonveaux, P., Lai, J. L., Vanrumbeke, M., Loucheux-Lefebvre, M. H., Bauters, F., Berger, R. & Kerckaert, J. P. (1992). Mutations of the p53 gene in acute myeloid leukemia. Br J Haematol 80: 178–183.
Fritsche, M., Haessler, C. & Brandner, G. (1993). Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8: 307–318.
Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W-W, Owen-Schaub, L. B. & Roth, J. A. (1994). Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54: 2287–2291.
Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E. & Shay, J. W. (1992). A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12: 2866–2871.
Gannon, J. V., Greaves, R., Iggo, R. & Lane, D. P. (1990). Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9: 1595–1602.
Gottlieb, T. M. & Oren, M. (1996). p53 in growth control and neoplasia. Biochim Biophys Acta 1285: 77–102.
Greenblatt, M. S., Bennet, W. P., Hollstein, M. & Harris, C. C. (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855–4878.
Hainaut, P. (1995). The tumor suppressor protein p53: a receptor to genotoxic stress that controls cell growth and survival. Curr Op Oncol 7: 76–82.
Hainaut, P. & Vähäkangas, K. (1997). p53 as a sensor of carcinogenic exposures: mechanisms of p53 protein induction and lessons from p53 gene mutations. Pathol Biol 45: 833–844.
Hall, P. A. & Lane, D. P. (1994). p53 in tumor pathology: can we trust immunohistochemistry? – revisited!. J Pathol 172: 1–4.
Hamblin, T. J. (1995). Disappointments in treating acute leukemia in the elderly. N Engl J Med 332: 1712–1713.
Harris, C. C. (1996). Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1442–1455.
Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sorlie, T., Hoving, E., Smith-Sorensen, B., Montesano, R. & Harris, C. C. (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22: 3551–3555.
Imamura, J., Miyoushi, I. & Koefller, P. (1994). p53 in hematological malignancies. Blood 84: 2412–2421.
Isobe, M., Emanuel, B., Gival, D., Oren, M. & Croce, C. (1986). Localization of gene for human p53 tumor antigen to band 17p13. Nature 320: 84–87.
Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304–6311.
Ko, L. J. & Prives, C. (1996). p53: puzzle and paradigm. Genes Dev 10: 1054–1072.
Kubbutat, M. H. G. & Vousden, K. H. (1997). Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol Cell Biol 17: 460–468.
Lehman, T. A., Bennett, W. P., Metcalf, R. A., Welsh, J. A., Ecker, J., Modali, R. V., Ullrich, S., Romano, J. W., Appella, E., Testa, J. R., Gerwin, B. I. & Harris, C. C. (1991). p53 mutations, ras mutations, and p53 heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 51: 4090–4096.
Levine, A. J. (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323–331.
Linzer, D. I. & Levine, A. J. (1979). Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43–52.
Lowe, S. W., Ruley, H. E., Jacks, T. & Houseman, D. E. (1993). p53 dependent apoptosis modulates the cytotoxicity of anticancer cells. Cell 74: 957–968.
Lu, X. & Lane, D. P. (1993). Differential induction of transcriptionally active p53 following UV or ionizing irradiation: defects in chromosome instability syndromes?. Cell 75: 765–778.
Lutzker, S. & Levine, A. J. (1996). A functionally inactive p53 protein in embryonal carcinoma cells is activated by DNA damage or cellular differentiation. Nature Med 2: 804–810.
Maki, C. G. & Howley, P. M. (1997). Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol 17: 355–363.
Maki, C. G., Huibregtse, J. M. & Howley, P. M. (1996). In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res 56: 2649–2654.
Marks, D. I., Kurz, B. W., Link, M. P., Ng, E., Shuster, J. J., Lauer, S. J., Brodsky, I. & Haines, D. S. (1996). High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 87: 1155–1161.
Mcbride, O. W., Merry, D. & Givol, D. (1986). The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci USA 83: 130–134.
Milner, J. (1994). Forms and functions of p53. Semin Cancer Biol 5: 211–219.
Milner, J. & Medcalf, E. A. (1991). Co-translation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65: 765–774.
Moll, O. M., Ostermeyer, A. G., Halady, R., Winkfield, B., Frazier, M. & Zambetti, G. (1996). Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol 16: 1126–1137.
Momand, J., Zambetti, G. P., Olson, D. C., George, D. & Levine, A. J. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 69: 1237–1245.
Peng, H. Q., Hogg, D., Malkin, D., Bailey, D., Gallie, B. L., Bulbul, M., Jewett, M., Buchanan, J. & Gross, P. E. (1993). Mutations of the p53 gene do not occur in testis cancer. Cancer Res 53: 3574–3578.
Rämet, M., Castren, K., Järvinen, K., Pekkala, K., Tupeenniemi-Hujanen, T., Soini, Y., Pääkkö, P. & Vähäkangas, K. (1995). p53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines. Carcinogenesis 16: 2117–2124.
Rämet, M., Turunen, S., Pääkkö, P., Laatio, L., Raunio, H., Hainaut, P. & Vähäkangas, K. (1998). Benzo(a)pyrene induces p53 and apoptosis but no G1 arrest in MCF-7 cells. (submitted)
Rivas, C. I., Wisniewski, D., Strife, A., Perez, A., Lambek, C., Bruno, S., Darzynkiewicz, Z. & Clarkson, B. (1992). Constitutive expression of p53 protein in enriched normal human marrow blast cell populations. Blood 79: 1982–1986.
Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Ferson, D. Z., Hong, W. K., Komaki, R., Lee, J. J., Nesbitt, J. C., Pisters, K. M. W., Putnam, J. B., Schea, R., Shin, D. M., Walsh, G. L., Dolormente, M. M., Han, C-I, Martin, F. D., Yen, N., Xu, K., Stephens, L. C., McDonnel, T. J., Mukhopadhyay, T. & Cai, D. (1996). Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 2: 985–991.
Schottelius, A., Brennscheidt, U., Ludwig, W-D, Mertelsmann, R. H., Herrmann, F. & Lübbert, M. (1994). Mechanisms of p53 alteration in acute leukemias. Leukemia 8: 1673–1681.
Selivanova, G. & Wiman, K. G. (1995). p53: a cell cycle regulator activated by DNA damage. Adv Cancer Res 66: 143–180.
Soini, Y., Turpeenniemi-Hujanen, T., Kamel, D., Autio-Harmainen, H., Risteli, J., Risteli, L., Nuorva, K., Pääkkö, P. & Vähäkangas, K. (1993). p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br J Cancer 68: 1029–1035.
Steegenga, W. T., van der Eb, A. J. & Jochemsen, A. G. (1996). How phosphorylation regulates the activity of p53. J Mol Biol 263: 103–113.
Sugimoto, K., Toyoshima, H., Sakai, R., Miyagawa, K., Hagiwara, K., Ishikawa, F., Takaku, F., Yazaki, Y. & Hirai, H. (1992). Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 79: 2378–2383.
Symonds, H., Krall, L., Remington, L., Saenz-Robies, M., Lowe, S., Jacks, T. & Van Dyke, T. (1994). p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703–711.
Tishler, R. B., Calderwood, S. K., Coleman, N. & Price, B. D. (1993). Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 53: 2212–2216.
Vähäkangas, K. H., Samet, J. M., Metcalf, R. A., Welsh, J. A., Bennett, W. P., Lane, D. P. & Harris, C. C. (1992). Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 339: 576–580.
Wada, H., Asada, M., Nakazawa, S., Itoh, H., Kobayashi, Y., Inoue, T., Fukumoro, K., Chan, L., Sugita, K., Hanada, R., Akuta, N., Kobayashi, N. & Mizutani, S. (1994). Clonal expansion of p53 mutant cells in leukemia progression in vitro. Leukemia 8: 53–59.
Welsh, J. A., Castren, K. & Vähäkangas, K. (1997). Single-strand conformation polymorphism analysis to detect p53 mutations: characterization and development of controls. Clin Chem 43: 2251–2255.
Zhang, W., Hu, G., Estey, E., Hester, J. & Deisseroth, A. (1992). Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene 7: 1645–1647.
Zhang, W., Lu, Q., Xie, Z-J & Mellgren, R. L. (1997). Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-leu-leu-tyr diazomethyl ketone: evidence that cleavage of p53 by a calpain-like protease is necessary for G1 to S-phase transition. Oncogene 14: 255–263.
Zhu, Y-M, Bradbury, D. & Russell, N. (1993). Expression of different conformations of p53 in the blast cells of acute myeloblastic leukaemia is related to in vitro growth characteristics. Br J Cancer 68: 851–855.
Zhu, Y-M, Bradbury, D. & Russell, N. (1994). Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. Br J Cancer 69: 468–47.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Zheng, A., Castren, K., Säily, M. et al. p53 status of newly established acute myeloid leukaemia cell lines. Br J Cancer 79, 407–415 (1999). https://doi.org/10.1038/sj.bjc.6690064
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690064
Keywords
This article is cited by
-
Combination of all-trans retinoic acid and interferon-gamma upregulated p27kip1 and down regulated CDK2 to cause cell cycle arrest leading to differentiation and apoptosis in human glioblastoma LN18 (PTEN-proficient) and U87MG (PTEN-deficient) cells
Cancer Chemotherapy and Pharmacology (2008)
-
Mapping normal and cancer cell signalling networks: towards single-cell proteomics
Nature Reviews Cancer (2006)
-
False leukemia–lymphoma cell lines: an update on over 500 cell lines
Leukemia (2003)
-
p53 alterations in human leukemia–lymphoma cell lines: in vitroartifact or prerequisite for cell immortalization?
Leukemia (2000)